X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
skeletal-related events (643) 643
humans (464) 464
zoledronic acid (455) 455
index medicus (436) 436
oncology (408) 408
bone neoplasms - secondary (320) 320
bone metastases (317) 317
metastasis (285) 285
male (268) 268
double-blind (251) 251
female (221) 221
bisphosphonates (213) 213
denosumab (188) 188
prostate cancer (188) 188
diphosphonates - therapeutic use (187) 187
cancer (183) 183
bone neoplasms - drug therapy (176) 176
care and treatment (174) 174
aged (163) 163
middle aged (161) 161
prostate-cancer (157) 157
bone density conservation agents - therapeutic use (153) 153
breast-cancer (151) 151
bone metastasis (150) 150
survival (141) 141
quality-of-life (140) 140
solid tumors (126) 126
breast cancer (124) 124
quality of life (120) 120
research (103) 103
skeletal-related event (103) 103
pain (98) 98
long-term efficacy (97) 97
imidazoles - therapeutic use (95) 95
prostatic neoplasms - pathology (94) 94
breast neoplasms - pathology (92) 92
placebo-controlled trial (91) 91
analysis (87) 87
complications (87) 87
treatment outcome (86) 86
disease (85) 85
bone cancer (83) 83
hematology, oncology and palliative medicine (82) 82
retrospective studies (81) 81
metastases (80) 80
pamidronate (80) 80
antineoplastic agents - therapeutic use (79) 79
adult (77) 77
health care sciences & services (74) 74
medicine & public health (74) 74
risk factors (73) 73
prevention (72) 72
aged, 80 and over (71) 71
multiple-myeloma (71) 71
pharmacology & pharmacy (68) 68
health aspects (66) 66
development and progression (65) 65
multiple myeloma (64) 64
phase-iii (64) 64
chemotherapy (63) 63
urology & nephrology (63) 63
diphosphonates - administration & dosage (62) 62
drug therapy (60) 60
prognosis (60) 60
bones (54) 54
cancer patients (54) 54
diphosphonates - adverse effects (54) 54
lung neoplasms - pathology (54) 54
men (52) 52
bone neoplasms - complications (51) 51
cancer therapies (50) 50
complications and side effects (50) 50
lung cancer (49) 49
review (49) 49
androgen-deprivation therapy (48) 48
bisphosphonate (48) 48
bone density conservation agents - adverse effects (47) 47
mortality (47) 47
neoplasm metastasis (47) 47
skeletal complications (47) 47
animals (46) 46
patients (46) 46
skeletal related events (46) 46
fractures (45) 45
prostatic neoplasms - drug therapy (44) 44
radiotherapy (44) 44
abiraterone acetate (43) 43
diagnosis (43) 43
randomized controlled trials as topic (43) 43
bone neoplasms - therapy (42) 42
imidazoles - administration & dosage (41) 41
incidence (40) 40
medicine, general & internal (40) 40
phosphonates (40) 40
clinical trials (39) 39
cost-effectiveness (39) 39
hematology (39) 39
lung-cancer (39) 39
therapy (39) 39
bone density conservation agents - administration & dosage (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (761) 761
French (15) 15
German (7) 7
Japanese (4) 4
Chinese (2) 2
Czech (2) 2
Spanish (2) 2
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Breast Cancer Research and Treatment, ISSN 0167-6806, 9/2011, Volume 129, Issue 2, pp. 495 - 503
Journal Article
Cancer, ISSN 0008-543X, 05/2017, Volume 123, Issue 9, pp. 1528 - 1535
BACKGROUND Skeletal‐related events (SREs) are common complications of bone metastatic castration‐resistant prostate cancer (mCRPC). To the authors' knowledge,... 
bone metastases | bone pain | prostate cancer | metastatic castration‐resistant prostate cancer (mCRPC) | skeletal‐related event (SRE) | metastatic castration-resistant prostate cancer (mCRPC) | skeletal-related event (SRE) | SURVIVAL | MORTALITY | PROGNOSTIC-FACTORS | DENOSUMAB | ZOLEDRONIC ACID | BREAST-CANCER | TRIAL | PAIN | ONCOLOGY | MEN | COMPLICATIONS | Multivariate Analysis | Bone Neoplasms - therapy | Follow-Up Studies | Pain - epidemiology | Fractures, Spontaneous - epidemiology | Radiotherapy - utilization | Humans | Bone Neoplasms - secondary | Bone Neoplasms - epidemiology | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Neoplasm Grading | Aged, 80 and over | Kallikreins - blood | Retrospective Studies | Bone Neoplasms - blood | Prostatic Neoplasms, Castration-Resistant - epidemiology | Prostatic Neoplasms, Castration-Resistant - blood | Risk Factors | Proportional Hazards Models | Spinal Cord Compression - epidemiology | Bone and Bones - surgery | Prostate-Specific Antigen - blood | Orthopedic Procedures - utilization | Aged | Cancer patients | Diagnosis | Health aspects | Prostate cancer | Identification methods | Complications | Prostate-specific antigen | Health risks | Clinical trials | Medical records | Risk reduction | Metastasis | Radiation therapy | Health care facilities | Risk analysis | Patients | Risk factors | Metastases | Bone cancer | Pain | Castration | Biopsy | Men | Mathematical models | Prostate | Cancer | skeletal related event (SRE)
Journal Article
Medicine (United States), ISSN 0025-7974, 12/2017, Volume 96, Issue 51, p. e9327
Because of improving treatments and survival, 40% to 58% of patients with bone metastases from nonsmall cell lung cancer (NSCLC) will suffer from at least one... 
skeletal-related events | bone metastasis | nonsmall cell lung cancer | survival | RISK-FACTORS | SAFETY | TUMORS | CHEMOTHERAPY | ZOLEDRONIC ACID | MEDICINE, GENERAL & INTERNAL | PREDICTORS | DOUBLE-BLIND | CARCINOMA | LONG-TERM EFFICACY | EPIDEMIOLOGY
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2014, Volume 167, Issue 3, pp. 366 - 375
Summary Dickkopf‐1 (DKK1), expressed by myeloma cells, suppresses osteoblast function and plays a key role in bone disease in multiple myeloma. BHQ880, a human... 
BHQ880 | multiple myeloma | Phase I | skeletal‐related event | Multiple myeloma | Skeletal-related event | BONE-DISEASE | DICKKOPF-1 | skeletal-related event | DKK1 | IN-VITRO | SERUM CONCENTRATIONS | OSTEOBLASTS | GROWTH | DOUBLE-BLIND | RECEPTOR-RELATED PROTEIN-5 | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Recurrence | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Imidazoles - administration & dosage | Antibodies, Monoclonal - therapeutic use | Male | Neoplasm Proteins - antagonists & inhibitors | Osteolysis - etiology | Molecular Targeted Therapy | Osteolysis - drug therapy | Multiple Myeloma - drug therapy | Hypertension - chemically induced | Diphosphonates - therapeutic use | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Diphosphonates - adverse effects | Anabolic Agents - therapeutic use | Bone Density Conservation Agents - adverse effects | Multiple Myeloma - complications | Imidazoles - adverse effects | Anabolic Agents - adverse effects | Bone Resorption - drug therapy | Antibodies, Monoclonal - pharmacokinetics | Bone Density Conservation Agents - therapeutic use | Fractures, Spontaneous - etiology | Diphosphonates - administration & dosage | Spinal Cord Compression - etiology | Bone Density Conservation Agents - administration & dosage | Bone Resorption - prevention & control | Maximum Tolerated Dose | Osteolysis - blood | Anabolic Agents - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Anabolic Agents - pharmacokinetics | Intercellular Signaling Peptides and Proteins - immunology | Medical research | Care and treatment | Relapse | Immunoglobulin G | Medicine, Experimental | Bones | Density | Diseases | Index Medicus
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 48, Issue 16, pp. 3082 - 3092
Journal Article
Lung Cancer, ISSN 0169-5002, 06/2019, Volume 132, pp. 59 - 64
•SMARCA4-DTS is a recently described lung cancer with an aggressive clinical course.•Severe SREs comprise a new significant clinical feature of... 
Skeletal related event | Lung cancer | SWI/SNF complex | SMARCA4 | Sarcoma | Analysis | Genomics
Journal Article
Journal Article